From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Bluebird at 2.5p worth 9.58p! Just a few caveats guv

By Tom Winnifrith | Friday 17 June 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Just a few caveats. Align Research is paid to pump out the research below. Align and its boss, Richard "nobody likes me and I don't care" Jennings own shed loads of shares in Bluebird Merchant Ventures (BMV), and the "analyst" is disgraced, journalist smearing, part time PR man, the vile and repellent Dr Michael Green. Dr Green should not be allowed to work in financial services after his crimes as an enabler of the fraud Sefton Resources (SER). Having said all of that, I too have an interest in these shares and reckon they are cheap. Are they worth 9.58p as the ludicrous Green suggests? Er no. But could they double? Yes. And the note below explains why.

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 18:00:21